Month-long educational and awareness initiative designed increase public awareness of the potential of cancer immunotherapy to treat and potentially cure all cancers.
1-Jun-2016 2:05 PM EDT Add to Favorites
One-day, multi-distance ride through the Lower Hudson Valley’s breathtaking landscape to raise funds for the nonprofit Cancer Research Institute and increase awareness of the potential of immunotherapy to cure all cancers.
12-May-2016 12:00 PM EDT Add to Favorites
CRI and Inspire have partnered to launch a new cancer immunotherapy support community for patients and caregivers.
11-Apr-2016 10:00 AM EDT Add to Favorites
Immunotherapy is currently revolutionizing cancer treatment and, according to Axel Hoos, M.D., Ph.D., has the potential to improve patient outcomes significantly in the future. Dr. Hoos leads one of the Cancer Research Institute’s (CRI)...
23-Mar-2016 11:05 AM EDT Add to Favorites
New hope now exists for patients with advanced kidney cancer. Yesterday, the FDA approved the immunotherapy drug nivolumab (Opdivo®, Bristol-Myers Squibb) to treat metastatic renal cell carcinoma (RCC)—the most common form of kidney cancer—that...
2-Dec-2015 2:05 PM EST Add to Favorites
Cancer Research Institute and Ludwig Cancer Research Partner with Targovax to Test Candidate Virotherapy in Early-Phase Clinical Trials
Targovax, a biotechnology company based in Oslo, has partnered with two nonprofit cancer research organizations to test its virotherapy product in early-phase combination clinical trials.
18-Nov-2015 8:00 AM EST Add to Favorites
Cancer Research Institute (CRI) is proud to announce that it will be participating in the Revlon LOVE IS ON Million Dollar Challenge, which runs now through October 29, 2015.
21-Sep-2015 12:05 PM EDT Add to Favorites
The Cancer Research Institute announced today the winners of the 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research. This annual award recognizes the contributions of individuals, corporations, and foundations that...
10-Aug-2015 9:05 AM EDT Add to Favorites
The FDA announced on Aug 4 2009 that tumor necrosis factor (TNF) blockers used in the treatment of immune disorders carry an increased risk of lymphoma and other cancers in children and adolescents. The discoverer of TNF-alpha, Lloyd J. Old, M.D., a...
7-Aug-2009 9:00 AM EDT
Dendreon's PROVENGE for the treatment of advanced prostate cancer is the first active cellular immunotherapy to prolong patient survival, according to data from a pivotal phase III clinical trial announced at yesterday's AUA annual meeting in...
29-Apr-2009 11:20 AM EDT